“Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis

• In: Poster presentation
• At: Buenos Aires (Argentina) (2016)
• Type: Poster
• Poster code: POS-HMIS-001
• By: ABRAHAM, Ivo (UNIVERSITY OF ARIZONA, Pharmacy Practice and Science, Tucson, United States)
• Co-author(s): Abdulaziz Alhossan:Center for Health Outcomes and PharmacoEconomic Research,UNIVERSITY OF ARIZONA,Tucson,United States;College of Pharmacy,King Saud University,Riyadh,Saudi Arabia|Chris Lee:School of Nursing and Medicine,Oregon Health & Science University,Portland ,United States|Karen MacDonald:,Matrix45,Tucson,United States|Ivo Abraham:Center for Health Outcomes and PharmacoEconomic Research,UNIVERSITY OF ARIZONA,Tucson,United States;,Matrix45,Tucson,United States;College of Pharmacy and College of Medicine,UNIVERSITY OF ARIZONA,Tucson,United States
  
• Abstract:

  A total of 25 studies have evaluated the effectiveness of omalizumab under “real-life” conditions of heterogeneity in patients, clinicians, sites, and treatment patterns.  

  We searched PubMed and Embase for real-life studies on omalizumab in severe asthma published up to 2015. Three effect size types were extracted: single-point proportions; mean+SD

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login